Special Awards
○ Dr. Tung Ta-Cheng’s Basic Cancer Research Award
Prior Recipients
2024Recipient
Wen-Chun Hung,Ph.D. (洪文俊)
Secretary General, National Health Research Institutes
2024Recipient
Wen-Chun Hung,Ph.D. (洪文俊)
Secretary General, National Health Research Institutes
❖ Educational Experiences
PhD, Institute of Medicine, Kaohsiung Medical University
❖ Professional Experiences
Director, Research Planning and Development, National Health Research Institutes
Vice President and Distinguished Professor, Kaohsiung Medical University
Deputy Director, National Institute of Cancer Research, National Health Research Institutes
Dean and Xi-Wan Chair Professor, College of Science, National Sun Yat-Sen University
Director, Institute of Biomedical Sciences, National Sun Yat-Sen University
❖ Awards & Honors
Outstanding Research Award for Memory Lecture of Pin-Wen Lin, The 13th International Pancreatic Cancer Conference, 2020
Chair, Domain of Microbiology, Immunology and Medical Technology, National Science Council, Taiwan, Republic of China,2010-2011
Xi-Wan Chair Professor, National Sun Yat-Sen University, 2009-2011
The 1st Yung Shin Lee Tian-De Medical and Pharmaceutical Science and Technology Awards-Young Scientist Research Scholarship, 2006
Outstanding Research Award, The Chinese Oncology Society, Republic of China, 2004
The Outstanding Research Award, National Science Council, Republic of China, 2003
2023Recipient
Yan-Shen Shan,MD.,Ph. D.(沈延盛)
College of Medicine, National Cheng Kung University
Department of Surgery, National Cheng Kung University Hospital
2023Recipient
Yan-Shen Shan,MD.,Ph. D.(沈延盛)
College of Medicine, National Cheng Kung University
Department of Surgery, National Cheng Kung University Hospital
❖ Current Position
成大醫學院 院長
成大醫學院 臨床醫學研究所 特聘教授
成大醫學院 外科學科 成大醫院外科部一般外科 特聘教授成大醫院主治醫師
❖ Educational Experiences
成大醫學院 臨床醫學研究所 博士
成大醫學院 學士後醫學系 醫學士
台大醫學院 復健醫學系 物理治療組 理學士
美國賓大腸胃學科 訪問學者
❖ Professional Experiences
2018~ Convener of pancreatic cancer, Ministry of Health and Welfare Phase III/IV Cancer Research Grant
2016~ MOST and MOHW, Taiwan Clinical Trial Consortium (TCTC) UGI cancer team leader
2017~2019 Chief, Institute of Clinical Medicine, NCKU
2016~2019 Director, Department of Clinical Medical Research, NCKUH
2012~2016 Professor, Institute of Clinical Medicine and Surgery, NCKU
2010~2016 Chief of Division of Trauma, Department of Surgery, NCKUH
2010~2018 Convener of UGI Cancer, NCKUH
2008~2012 Associate professor, Institute of Clinical Medicine, NCKU
❖ Awards & Honors
2021-2023 Gold Medal, Paper Award of International College of Surgeons
2018~ Asian-Oceanic Pancreatic Association (AOPA) (member of a council)
2020 成功大學李國鼎榮譽學者
2020 科技部傑出研究獎
2018 Outstanding cancer research award,中華民國癌症醫學會徐千田傑出研究獎, Taiwan
2019 Annual conference of American, Academic Surgical Congress (ASC), Invited Representative Speaker of Taiwan Surgery Society (AAS
international guest)
2018 Pancreas, The best post award, Baltimore, Maryland.2016The annual best paper of clinical medicine, College of Medicine, NCKU
2022Recipient
Shih-Hsien, Hsu Ph. D.(許世賢)
Graduate Institute of Medicine, Kaohsiung Medical University
2022Recipient
Shih-Hsien, Hsu Ph. D.(許世賢)
Graduate Institute of Medicine, Kaohsiung Medical University
Position : Professor, Graduate Institute of Medicine, Kaohsiung Medical University (KMU)
- Present Job:
- Aug. 2018-Now Director of Master’s program, Graduate Institute of Medicine, Kaohsiung Medical University (KMU).
- Aug. 2017-Now Professor, Graduate Institute of Medicine, Kaohsiung Medical University (KMU).
- Aug. 2019-Now Voice CEO, Center of Applied Genomics, Kaohsiung Medical University (KMU)
Ph. D.: 1996-2001 National Defense Medical Center, Taipei, Taiwan,
(Laboratory: Dr. Hung Li (Institute of Molecular Biology, Academia Sinica.)
Expertise:
- Development Biology
- Gene transcription and Regulation
- Molecular oncology
- Immunotherapy
- Hepatology
- Oncogene
- Cell Death & Disease
- Molecular therapy
- Cancers
- Biomedicines
- Pharmaceutical composition of regulating the expression level of survival of motor neuron 1 and method of detecting enzyme activity of ubiquitin carboxyl-terminal hrdrolase L1 in human fibroblasts TW:100104844; US:13/032846.
- Method of regulating the expression level of survival of motor neuron 1. US 9,045,793B2. (2015.06.09)
- 104015-TW, 105T-11-052-080.
- 107020-TW (I723562): MICE MODEL FOR LIVER PATHOLOGICAL CHANGES AND USE THEREOF.
Awards and Honors:
-
-
-
- 2000. Excellent Poster Award, 8th Symposium on Recent Advences in Cellular and Molecular Biology.
- 2001. Excellent Poster Award, 9th Symposium on Recent Advences in Cellular and Molecular Biology.
- 2007. Excellent Poster Award, 15th Symposium on Recent Advences in Cellular and Molecular Biology.
- 2010. Excellent Poster Award, 25th Symposium on Recent Advences in Cellular and Molecular Biology.
- 2011. Outstanding Research award, Kaohsiung Medical University.
- 2013-2014. Travel Grant award, 72nd -73rd Annual Meeting of The Japanese Cancer Association (JCA).
- 2013-2014. Outstanding Research award, Kaohsiung Medical University
- 2014 Liver Disease Prevention Research Foundation Fellowship.
- 2018-2021. Outstanding Research award, Kaohsiung Medical University.
- 2018. Annual excellent research project funding, Kaohsiung Medical University.
- 2018, 2120-2022 Special Outstanding Talents of the Ministry of Science and Technology Awards, Ministry of Science and Technology, R.O.C., Taiwan.
- 2022, Dr. Tung Ta-Cheng’s Basic Cancer Research Award.
-
-
Publications:
- Li-Ting Wang, Kwei-Yan Liu , Shyh-Shin Chiou, Shau-Ku Huang, Shih-Hsien Hsu*, Shen-Nien Wang*. Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance. Cancer letters Cancer Lett. 2021 Jul 12; 520: 160-171.
- Chuang KT, Wang SN, Hsu SH, Wang LT. Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity. Cancer Med. 2021 Aug;10(16):5545-5556.
- Li-Ting Wang#, Ming-Hong Lin#, Kwei-Yan Liu, Shyh-Shin Chiou, Shen-Nien Wang, Chee-Yin Chai, Li-Wen Tseng, Hsin-Ying Clair Chiou, Hsueh-Chun Wang, Kazunari K. Yokoyama, Shih-Hsien Hsu*, Shau-Ku Huang*. WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism. Autophagy. 2021 Dec;17(12):4202-4217.
- Kwei-Yan Liu, Li-Ting Wang, Hsueh-Chun Wang, Shen-Nien Wang, Li-Wen Tseng, Chee-Yin Chai, Shyh-Shin Chiou, Shau-Ku Huang*, Shih-Hsien Hsu*. Aryl Hydrocarbon Receptor is Essential in the Control of Lung Club Cell Homeostasis. 2021 Jan. Journal of Inflammation Research 2021 Feb 5;14:299-311.
- Wang LT, Liu KY, Jeng WY, Chiang CM, Chai CY, Chiou SS, Huang MS, Yokoyama KK, Wang SN, Huang SK, Hsu SH*. PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition. EMBO Rep. 2020 Feb 5;21(2):e48795. Highlighted by scrolling marquee of EMBO Reports.
- Liu KY, Wang LT, Hsu SH*, Wang SN*. Homeobox Genes and Hepatocellular Carcinoma. Cancers (Basel). 2019 May 3;11(5). pii: E621. (Invited review)
- Wang LT, Wang SN, Chiou SS, Liu KY, Chai CY, Chiang CM, Huang SK, Yokoyama KK, Hsu SH*. TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer. Oncogene. 2019 Jan;38(4):518-532. doi: 10.1038/s41388-018-0457-z. [Epub ahead of print]
- Chiu YH#, Hsu SH#, Hsu HW, Huang KC, Liu W, Wu CY, Huang WP, Chen JY, Chen BH, Chiu CC. Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. Int J Oncol. 2018 Nov;53(5):1967-1979. (# equal contribute to this manuscript)
- Wang HC, Wong TH, Wang LT, Su HH, Yu HY, Wu AH, Lin YC, Chen HL, Suen JL, Hsu SH, Chen LC, Zhou Y, Huang SK. Aryl hydrocarbon receptor signaling promotes ORMDL3-dependent generation of sphingosine-1-phosphate by inhibiting sphingosine-1-phosphate lyase. Cell Mol Immunol. 2018 Mar 23. doi: 10.1038/s41423-018-0022-2.
- Liu KY, Wang LT, Hsu SH*. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma. Cancers (Basel). 2018 Jan 3;10(1). pii: E8. (Invited review)
- Wang YS, Hsi E, Cheng HY, Hsu SH, Liao YC, Juo SH. Let-7g suppresses both canonical and non-canonical NF-κB pathways in macrophages leading to anti-atherosclerosis. Oncotarget. 2017 May 23. doi: 10.18632/oncotarget.18197.
- Li-Ting Wang, Shyh-Shin Chiou, Chee-Yin Chai, Edward Hsi, Kazunari K. Yokoyama, Shen-Nien Wang, Shau-Ku Huang, Shih-Hsien Hsu*. Intestine-specific homeobox gene ISX integrates interleukin-6 signaling, tryptophan metabolism, and immune suppression. Cancer Research. 2017 Aug 1;77(15):4065-4077.
- Hsu SH*, Wang LT, Chai CY, Wu CC, Hsi E, Chiou SS, Wang SN. Aryl hydrocarbon receptor promotes hepatocellular carcinoma tumorigenesis by targeting intestine-specific homeobox expression. Mol Carcinog. 2017 Oct;56(10):2167-2177.
- Wang LT, Chiou SS, Chai CY, Hsi E, Chiang CM, Huang SK, Wang SN, Yokoyama KK, Hsu SH*. Transcription factor SPZ1 promotes TWIST-mediated epithelial- mesenchymal transition and oncogenesis in human liver cancer. Oncogene. 2017 Aug;36(31):4405-4414.
- Wang LT, Chiou SS, Chai CY, Hsi E, Wang SN, Huang SK, Hsu SH*. Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma. Oncotarget. 2017 Jan 31;8(5): 7489-7501.
- Chen CY, Yen CY, Wang HR, Yang HP, Tang JY, Huang HW, Hsu SH*, Chang HW*. Tenuifolide B from Cinnamomum tenuifolium Stem Selectively Inhibits Proliferation of Oral Cancer Cells via Apoptosis, ROS Generation, Mitochondrial Depolarization, and DNA Damage. Toxins (Basel). 2016 Nov 5;8(11).
- Wang SN, Wang LT, Sun DP, Chai CY, Hsi E, Kuo HT, Yokoyama KK, Hsu SH*. Intestine-specific homeobox (ISX) upregulates E2F1 expression and related oncogenic activities in HCC. Oncotarget. 2016 Jun 14;7(24):36924-36939.
- Chen WC, Tseng CK, Chen YH, Lin CK, Hsu SH, Wang SN, Lee JC*. HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway. PLoS One. 2015 Jul 31;10(7):e0133264.
- Shyh-Shin Chiou; Li-Ting Wang; Shih-Bo Huang; Chee-Yin Chai; Shen-Nien Wang; Yu-Mei Liao; Pei-Chin Lin; Kwei-Yan Liu; Shih-Hsien Hsu*. Wntless (GPR177) expression correlates with poor prognosis in B-cell precursor acute lymphoblastic leukemia via Wnt signaling. Carcinogenesis 2014 35 (10):2357-2364.
- Li-Ting Wang, Shyh-Shin Chiou, Yu-Mei Liao, Yuh-Jyh Jong, Shih-Hsien Hsu* Survival of motor neuron protein downregulates miR-9 expression in patients with spinal muscular atrophy. Kaohsiung Journal of Medical Sciences 2014 (30), 229-234.
2021Recipient
Eric Y. Chuang, Sc.D., EMBA (莊曜宇)
Collage of Biomedical Engineering, China Medical University
2021Recipient
Eric Y. Chuang, Sc.D., EMBA (莊曜宇)
Collage of Biomedical Engineering, China Medical University
❖ Education & Training Background: ⎢ View full profile ⎢
2015-2017 EMBA, National Taiwan University, Taipei, Taiwan
1991-1997 Sc.D. Cancer Biology, Harvard University, School of Public Health, Boston, MA
1990-1991 M.S. Biology, Illinois Institute of Technology, Chicago, IL
1982-1986 B.S. Biology, Tunghai University, Taichung, Taiwan
❖ Emplyment History:
2021-present Dean, Collage of Biomedical Engineering, China Medical University, Taichung, Taiwan
2021-present Professor, Master program for Biomedical Engineering, China Medical University, Taichung, Taiwan
2018-2021 Deputy General Director, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan
2016-present Joint Appointment Research Fellow, Genomics Research Center, Academia Sinica, Taipei, Taiwan
2015-2020 Deputy Director, Research and Development Center for Medical Devices, National Taiwan University, Taipei, Taiwan
2012-2018 Director and Professor, Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan
2011-2017 Director, NTU Yonglin Biomedical Engineering Center, National Taiwan University, Taipei, Taiwan
2011-present Research Fellow, Center of Biotechnology, National Taiwan University, Taipei, Taiwan
2011-present Professor, Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan
2010-present Professor, Genome and Systems Biology Degree Program, College of Life Science, National Taiwan University, Taipei, Taiwan
2008-present Professor, Graduate Institute of Biomedical Electronics and Bioinformatics/Department of Electrical Engineering, National Taiwan University, Taipei, Taiwan
2008-present Professor, Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan
2008-present Professor, Department of Life Science, National Taiwan University, Taipei, Taiwan
2005-present Principal Investigator, Bioinformatics and Biostatistics Core, NTU Center of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan
2004-present Faculty Affiliate, Department of Environmental & Radiological Health Sciences, Colorado State University, Fort Collins, CO
2009-2011 Program Director, Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD
2007-2008 Associate Professor, Graduate Institute of Epidemiology, National Taiwan University, Taipei, Taiwan
2006-2008 Associate Professor, Department of Life Science, National Taiwan University, Taipei, Taiwan
2006-2008 Associate Professor, Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan
2004-2008 Associate Professor, Department of Electrical Engineering, National Taiwan University, Taipei, Taiwan
2000-2005 Head, Microarray Laboratory, Radiation Oncology Sciences Program, National Cancer Institute, National Institutes of Health, Gaithersburg, MD
1998-2000 CRTA Fellow, Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
1997-1998 Postdoctoral Research Fellow, Department of Cancer Cell Biology, Harvard University, School of Public Health, Boston, MA
1991-1997 Graduate Study Research, Laboratory of Radiobiology, Harvard University, Boston, MA
1986-1988 Research Assistant, Cell Biology Laboratory, Academia Sinica, Institute of Zoology, Taipei, Taiwan
2020Recipient
Min-Hsiung Pan, Ph.D. (潘敏雄)
Institute of Food Science and Technology, NTU
❖ Education & Training Background: ⎢ View full profile ⎢
1996-2000 Ph.D., College of Medicine, NTU Taiwan Biochemistry and Molecular Biology
❖ Emplyment History:
2015/08-Now Distinguished Professor, Institute of Food Science and Technology, NTU
2018/08-Now Director, Institute of Food Science and Technology, NTU
2013/08-2015/07 Professor, Institute of Food Science and Technology, NTU
2012/08-2013/07 Dean/Professor, Research & Development Affairs, NKMU
2011/08-2012/07 Associate Dean/Professo, Academic Affairs, NKMU
2019Recipient
Hung-Yun Lin, Ph.D. (林宏惲)
Taipei Medical University Research Center of Cancer Translational Medicine
2019Recipient
Hung-Yun Lin, Ph.D. (林宏惲)
Taipei Medical University Research Center of Cancer Translational Medicine
❖ Biography: ⎢ View full profile ⎢
Dr. Lin received his PhD degree at SUNY Buffalo in 1991. He joined Dr. Paul J. Davis’ group to work with non-genomic activities of thyroid hormone in 1993. Dr. Lin has served at the VA Hospital and Ordway Research Institute in Albany, NY as a senior scientist. Later, he worked at the Pharmaceutical research Institute (PRI) at the Albany College of Pharmacy and Health Sciences, Albany, NY. Dr. Lin joined Taipei Medical University as full professor in 2012. For the past three years, his research has focused on mechanisms involved in thyroid hormone-induced pathogenesis in colorectal cancer and other types of cancers. His group has discovered that thyroid hormone promotes β-catenin and downstream HMGA-2 activation, in addition to integrin αvβ3-dependent signal transduction, to stimulate cell proliferation in colorectal cancer. A similar mechanism may play important roles in other types of cancer cells. He was invited to host Resveratrol2016 at Taipei Medical University. Finally, he also led an integrated team for an innovation new company competition and won the Outstanding Award given by the Ministry of Education of Taiwan. His laboratory is the first to develop an in vitro perfusion bellows cell culture system to study pharmacokinetics and pharmacodynamics of anti-cancer agents, and results of IC50 studies have been confirmed in xenografts. With help from the core facilities of Taipei Medical University, Dr. Lin’s group is able to conduct studies of PK of each agent, flow cytometry of cell cycle arrest gene signature, and translational xenograft. Data analyses of pharmaco-modeling are conducted by colleagues at PRI.
2018Recipient
Sen-Yung Hsieh, M.D., Ph.D.(謝森永)
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center
Department of Microbiology and Immunology, College of Medicine, Chang Gung University
2018Recipient
Sen-Yung Hsieh, M.D., Ph.D.(謝森永)
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center
Department of Microbiology and Immunology, College of Medicine, Chang Gung University
❖ Biography: ⎢View full profile ⎢
Dr. Sen-Yung Hsieh earned his M.D. degree from the National Yang Ming University, and Ph.D. in Molecular Virology from the University of Pennsylvania (sponsored by a government scholarship). He then completed his clinical training in internal medicine with a specialty in hepato-gastroenterology in Chang Gung Memorial Hospital (CGMH), Linkou, Taiwan. Currently, he is Professor of Medicine and Microbiology and Immunology at the Chang Gung University (CGU) and Professor of Internal Medicine and Hepato-Gastroenterology at CGMH (since 2005). He was entitled to establish the Clinical Proteomics Lab at CGMH in 2003. He was the former Director of Department of Medical Research of the hospital from 2010 to 2016. Under the supervision of the CGMH foundation leadership, he had led a multidisciplinary team designing and constructing the new research building for the hospital (2010-2017). He is now the head of the Department of Gastroenterology and Hepatology, Linkou CGMH.
He initially focused on the molecular virology and epidemiology of human hepatitis viruses. His team for the first time identified the zoonotic transmission of hepatitis E virus from pigs to humans in 1998. Since 2010 pigs have been proven as the primary transmitting source of acute hepatitis E, which leads to more than 100,000 cases each year in Europe. Currently, Dr. Hsieh is interested in elucidation the molecular mechanisms involving in carcinogenesis of human hepatoma. By integration of genomics, proteomics, functional genomics and mol and cellular biology approaches, he has identified several novel genes and pathways that play significant roles in the oncogenesis of human hepatoma. He discovered the Her2/Her3—Neuregulin autocrine loop in human hepatoma cells, which contributes to tumor invasion and metastasis and is involved in resistance to EGFR-targeted therapies in some of the human cancers. Recently, his group unveiled the mystery of how large tumors tend to invade and disseminate systemically. He found that actin cytoskeleton remodeling induced by intrinsic or microenvironmental cues can drive EMT reprogramming via induction of HIF and NOTCH signaling in a cell-density-dependent manner. Dr. Hsieh sought to elucidate the reason why the hepatoma incidence in Taiwan (35/100,000) is much higher than in other viral hepatitis prevalent countries in the world. Via a collaboration with Dr. BT Teh and Dr. Steven Rozen at the National Singapore University, he found that 78% (77/98) of HCCs contain aristolochic acid (AA) mutational signature, highest in the world (China, 47%; Korea, 13%; Japan, 2.7%; North America, 5%; Europe, 2%; Ng et al., Sci Transl Med, 2017). AA, present in some TCM and herbs, is most mutagenic to humans and related to many urinary tract cancers. These findings indicate widespread use of AA-containing TCM or remedies in our patients with chronic liver disease, which further promotes tumor development. Dr. Hsieh hopes to use this objective scientific evidence to urge patients with chronic hepatitis and cirrhosis to follow the physician's instructions but not take any folk remedies. His studies have been recognized by many domestic and international academic societies, including Outstanding Research Awards from Prof Song JL foundation (1994), Taiwan Medical Association (1999), Jap Soci Liver Study (2002), Chang Gung University (2013), Ministry of Science and Technology Outstanding Research Award (2017), Dr. Ta-Cheng Tung’s Basic Cancer Research Award (2018), and American Association for Cancer Research (AACR Team Science Award, 2018).
2017Recipient
Kelvin K. Tsai, M.D., Ph.D.(蔡坤志)
Laboratories for Tumor Aggressiveness and Stemness (The TAS Lab),NICR, NHRIs
Laboratory of Advanced Molecular Therapeutics (The AMT Lab),Graduate Institute of Clinical Medicine, Taipei Medical University
2017Recipient
Kelvin K. Tsai, M.D., Ph.D.(蔡坤志)
Laboratories for Tumor Aggressiveness and Stemness (The TAS Lab),NICR, NHRIs
Laboratory of Advanced Molecular Therapeutics (The AMT Lab),Graduate Institute of Clinical Medicine, Taipei Medical University
❖ General Profile: ⎢View full profile⎢Linkedin profile⎢Lab Webpage⎢
Dr. Tsai is a rigorously trained physician-scientist focusing on basic and translational research in cancer. He specializes in tumor epigenetics, tissue architecture, therapeutic resistance and cancer stemness, with a career goal aiming at targeting and treating metastasis and treatment resistance, the two major reasons for cancer mortality. Dr. Tsai graduated with a MD in 1993 from Taipei Medical University, Taiwan, and completed his clinical training and was board certified in internal medicine, gastroenterology and GI oncology. Dr. Tsai earned his PhD in 2005 in Genetics and Complex Diseases from Harvard University, USA. During his PhD work Dr. Tsai established novel three-dimensional coculture models to interrogate stromal-epithelial interactions. In 2007, he joined Valerie M. Weaver's Laboratory at UCSF to study a novel epigenetic mechanism in cancer drug resistance. Following his postdoc research Dr. Tsai funded the Laboratories for Tumor Aggressiveness and Stemness (The TAS Lab) and rose to the Associate Investigator at National Institute of Cancer Research in National Health Research Institutes, Taiwan. He has published first or corresponding author papers in top-notch journals such as Gastroenterology, JACC, Gut, and JEM, and he also served as the PI of several GI-cancer-related clinical trials. His major scientific achievements include the identification of a novel regulator for Wnt signaling and cancer stem cells, ASPM, and a master regulator of de novo treatment resistance in most cancers, N-CoR2. Dr. Tsai’s breakthrough findings along these lines of research have yielded a number of issued or pending global patents and he is now actively collaborating with academic and industrial sectors worldwide aiming at developing novel cancer therapeutics.
2016Recipient
Rita Yen-Hua Huang,Ph.D.(黃彥華)
Department of Biochemistry and Molecular Cell Biology,Graduate Institute of Medical Sciences,College of Medicine,Taipei Medical University(TMU)
TMU Center for Cell Therapy and Regeneration Medicine,TMU GTP Laboratory
2016Recipient
Rita Yen-Hua Huang,Ph.D.(黃彥華)
Department of Biochemistry and Molecular Cell Biology,Graduate Institute of Medical Sciences,College of Medicine,Taipei Medical University(TMU)
TMU Center for Cell Therapy and Regeneration Medicine,TMU GTP Laboratory
❖ Education:
1994-1997 Ph.D. in Biochemistry, National Taiwan University, Taipei, Taiwan
1991-1993 M.S. in Biochemistry, National Taiwan University, Taipei, Taiwan
1985-1989 B.S. in Chemistry, National Taiwan Normal University, Taipei, Taiwan
❖ Research Focus:
- Niche regulation of pluripotency in embryonic stem cell and somatic cancer
- Embryonic pluripotency and germ stem cell development
- Immuno-modulation and disease therapeutic potential of human placenta stem cells
❖ Honors/Awards:
2015 The International Top Journal Research Award of Taipei Medical University
2015 The Excellent Prize Research Award of Taipei Medical University
2015 The Prize Oral Award, 2015 Taiwan Society For Stem Cell Research (2015 TSSCR),Taipei, Taiwan
2014 2014~2016 Stem Cell Highlighting Program Project, Ministry of Science Technology (MOST), Executive Yuan, Taiwan.
2013 2013 Faculty Award of Taipei Medical University in Excellence of Teaching, Administration, and Research.
2013 The First Prize Oral Award, 2013 TSRM, Annual Meeting of Taiwan Society for Reproductive Medicine, Taiwan
2012 2012~2015 Outstanding Young Scientist Research Grant, Ministry of ScienceTechnology (MOST), Executive Yuan, Taiwan
2012 2012~2015 Stem Cell Highlighting Program Project, Ministry of Science Technology (MOST), Executive Yuan, Taiwan.
2012 2012 The Best Teacher Award, School of Medicine, Taipei Medical University, Taiwan
2011 The First Prize Award of Excellent Research, “Taipei Medical University, Taipei, Taiwan
2011 The Best Teacher Award, School of Medicine, Taipei Medical University, Taipei, Taiwan
2010 Faculty Award of Taipei Medical University in Teaching
2008 2008~2011 Stem Cell Highlighting Program Project, Ministry of Science Technology (MOST), Executive Yuan, Taiwan.
2015Recipient
Ya-Wen Cheng,Ph.D.(鄭雅文)
Graduate Institute of Cancer Biology and Drug Discovery,Taipei Medical University
2015Recipient
Ya-Wen Cheng,Ph.D.(鄭雅文)
Graduate Institute of Cancer Biology and Drug Discovery,Taipei Medical University
❖ Research Field:
- HPV-infected lung tumorigenesis
- MicroRNA expression profile in colon and breast cancer
- The role of microRNA in HCV-infected hepatocellular carcinoma therapy
- Colorectal cancer research
- Pterygium pathogenesis
❖ Education:
Ph.D. Institute of Medicine, Jan 2002,Chung Shan Medical University, Taiwan, R.O.C.
M.S. Institute of Toxicology, June 1998,Chung Shan Medical & Dental College, Taiwan, R.O.C.
B.S. Department of Medical Technology, June 1996,Chung Shan Medical & Dental College, Taiwan, R.O.C.
❖ Positon Helded:
8/2011~date Professor & Director,Graduate Institute of Cancer Biology and Drug Discovery,Taipei Medical University
2/2009~2011/07 Professor, Institute of Medicine,Chung Shan Medical University, Taiwan, R.O.C.
12/2005~1/2009 Associate Professor, Institute of Medicine,Chung Shan Medical University, Taiwan, R.O.C.
8/2002~11/2005 Assistant Professor, Institute of Medicine,Chung Shan Medical University, Taiwan, R.O.C.
2/2002~7/2002 Postdoctoral fellow, Institute of Toxicology,Chung Shan Medical University, Taiwan, R.O.C.
❖ Honors:
2009/03/06~2009/03/09 The 17th Annual Meeting of Asian Society for Cardiovascular and Thoracic Surgery(Invitee Speaker; Young Scientist Award)
2009/07/06~2009/07/08 The 36th Annual Meeting of the Japanese Society of Toxicology(Young Scientist Award)
2010/06~2010/10 Department of Molecular Pharmacology, Beckman Research Institute, City of Hope, National Medical Center(Visiting Professor)
2015/05/03 Dr. Dong Dacheng Award of Excellent Basic Medical Cancer Research
2014Recipient
Shih-Hwa Chiou,M.D.,Ph.D.(邱士華)
Department & Institute of Pharmacology, College of Medicine National Yang-Ming University
2014Recipient
Shih-Hwa Chiou,M.D.,Ph.D.(邱士華)
Department & Institute of Pharmacology, College of Medicine National Yang-Ming University
2013Recipient
Yi-Ching Wang,Ph.D.(王憶卿)
Department of Pharmacology & Institute of Basic Medical Sciences,College of Medicine,National Cheng Kung University
2013Recipient
Yi-Ching Wang,Ph.D.(王憶卿)
Department of Pharmacology & Institute of Basic Medical Sciences,College of Medicine,National Cheng Kung University
❖ Research Interests:
Dr. Wang studies the molecular mechanisms involved in lung tumorigenesis. Her group investigates the etiological association of alterations in tumor suppressor genes and oncogenes with lung tumorigenesis. The alteration analyses include the following aspects: gene mutation and polymorphism, gene amplification and loss, hypermethylation of promoter, chromatin structure alteration of gene locus, mRNA alteration, and protein expression alteration. More recently, Dr. Wang has continued to do research on cancer genomics and epigenomics such as array comparative genomic hybridization, and genome-scanning approaches of DNA methylation and chromatin alteration profiles for identification of new genes critical to lung tumorigenesis. Several potential anti-cancer drugs also are developing in her laboratory.
❖ Education:
1983~1987 B.Sc.(Horticulture), Chinese Culture University
1988-1993 Ph.D.(Genetics), Michigan State University
❖ Positions and Employment:
1993~1995 Post-doctoral fellow, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
1995~1999 Associate Professor, Institute of Toxicology, Chung Shan Medical Univ., Taichung, Taiwan
1999~2006 Professor, Department of Life Science, National Taiwan Normal Univ., Taipei, Taiwan
2006~present Distinguished Professor, Department of Pharmacology & Institute of Basic Medical Sciences & Institute of Clinical Medical Sciences, National Cheng Kung University, Tainan,Taiwan
❖ Awards:
2004, 2010, 2014 Outstanding research award of Ministry of Science and Technology, Taiwan
2007 Distinguished alumnus of Chinese Culture University, Taiwan
2007~2013 Research award of Cheng-Shin Medical Foundation, Taiwan
2008 Outstanding research award, Pharmacology Society, Taiwan
2010 Outstanding research award, College of Medicine, National Cheng Kung University, Taiwan
2013 Outstanding research award of Basic Research, The Chinese Oncology Society, Taiwan
2012Recipient
Yuan-Soon Ho,Ph.D.(何元順)
Institute of Biomedical Technology, Taipei Medical University
❖ General Profile:
Upon completion of my doctorate in biochemistry at the National Taiwan University in 1994, I joined the faculty of the Graduate Institute of Biomedical Technology, Taipei Medical University, where I directed research combining basic genomics and breast cancer research with translational research. My major research interests are the molecular mechanisms of environmentally and chemically induced carcinogenesis, drug-induced apoptosis and cell cycle disruption. Recently, my research has focused on the analysis of the mechanisms involving nicotinic receptors in human breast cancer formation. These findings led to the development of powerful antitumor agents, and the cloning of a nicotinic receptor gene linked to breast cancer has led to investigation of this receptor as a potential therapeutic target for smoking-induced breast cancer and other cancers. I was voted chairman of the Translational Cancer Research Center at the Taipei Medical University in 2009. This work will further establish a translational research team in which basic and clinical researchers collaborate to focus on the mechanisms of breast cancer formation.
❖ Education:
1990–1994: Ph.D. (Biochemistry), National Taiwan University, College of Medicine, Taipei, Taiwan, Republic of China
❖ Professional Experience:
1994–1995 Postdoctoral Researcher, National Taiwan University, College of Medicine, Taipei, Taiwan, ROC
1995–2001 Associate Professor, Institute of Biomedical Technology, Taipei Medical College, Taipei, Taiwan, ROC
2001–2004 Professor, Institute of Biomedical Technology, Taipei Medical University, Taipei, Taiwan, ROC
2002–2004 Chairman, School of Medical Technology, Taipei Medical University, Taipei, Taiwan, ROC
2002–2004 Chairman, Graduate Institute of Biomedical Technology, Taipei Medical University, Taipei, Taiwan, ROC
2011–2011 Chairman, Translational Cancer Research Center, Taipei Medical University, Taipei, Taiwan, ROC
2014~ Distinguished professor, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University
2015~ Director, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University
❖ Awards and Honors:
- The Best Research Award of the Chinese Oncology Society: Prof. Tung Da-Cheng's The Best Research Award (2012).
- Excellent Research Award of the National Science Council (1995–1996, 1998–2002); Excellent Research Award of the Taipei Medical University (2009, 2011, 2012)
- Bronze Research Award, Taipei Medical University (2000–2001)
- Bronze Research Award, Taipei Medical University (2003)
- Excellence in Innovation of Teaching Methods, Taipei Medical University (2000)
- listed in Who's Who in Medicine and Healthcare (21st edition, 2002–2007)
- listed in Who's Who in Science and Engineering (21st edition, 2003–2007)
- listed in Who's Who in the World (21st edition, 2003–2007)
2011Recipient
Hsing-Pang Hsieh,Ph.D.(謝興邦)
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes
2011Recipient
Hsing-Pang Hsieh,Ph.D.(謝興邦)
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes
2010Recipient
Shwu-Bin Lin,Ph.D.(林淑萍)
Department of Laboratory Sciences and Medical Biotechnology,National Taiwan University
Consultant, TRINEO Biotechnology Co., LTD.
2010Recipient
Shwu-Bin Lin,Ph.D.(林淑萍)
Department of Laboratory Sciences and Medical Biotechnology,National Taiwan University
Consultant, TRINEO Biotechnology Co., LTD.
❖ General Profile:
Shwu-Bin Lin, PhD, is professor of National Taiwan University, Department of Laboratory Sciences and Medical Biotechnology, and consultant of TRINEO Biotechnology Company. Dr. Lin’s research focuses on studying the efficacy of purified phytochemicals as anticancer or chemopreventive compound for pharmaceutical and neutraceutical innovation of folk medicinal plants. The research contents emphasize mechanistic study of the phytochemical’s effects on novel cellular signal transduction pathway or on known drug targets. Her research has helped translation of anticancer triterpenoid from Ganoderma to commercial products.
2009Recipient
Che-Ming Teng,Ph.D.(鄧哲明)
Department of Pharmacology, NTUMC
❖ Academic Degrees:
1964-1968 B.S. in Pharmacy, Kaohsiung Medical College
1969-1972 M.S. Pharmacological Institute, College of Medicine, National Taiwan University (NTUMC)
1973-1977 Ph.D. Pharmacological Institute, NTUMC
❖ Present Position:
1984- Professor, Department of Pharmacology, NTUMC
❖ Professional Experiences:
1970-1973 Assistant, Department of Pharmacology, NTUMC
1973-1978 Lecturer, Department of Pharmacology, NTUMC
1979-1981 Research Associate (NIH Forgaty International Fellowship), Department of Physiology, College of Medicine, Wayne State University, Michigan, U.S.A.
1978-1984 Associate Professor, Department of Pharmacology, NTUMC
1988-1990 Chairman, Experimental Animal Center, NTUMC
1990-1996 Chairman, Department of Pharmacology, NTUMC
1996-1998 Team Leader, Drug Research and Development Group, NTUMC
2010-2004 Associate Dean, Office for Research and Development, NTUMC
2003-2010 Chief Leader, National Science and Technology Program for Biotechnology and Pharmaceuticals (NSTPBP)
❖ Research Awards:
1985-1997 Outstanding Research Award, National Science Council
1988 Chong-Shan Research Award
1990 Distinguishing Achievement Award for Science and Technology, Executive Yuan
1994 Dr. Tsung-Ming Tu's Memorial Lecture Award
1994 Academic Award, Ministry of Education
1996 Ho Chin-Tui Outstanding Award
2002 Lifu Academic Award for Chinese Medicine
2005 Outstanding Achievement Award in Science and Technology, Executive Yuan
2009 Dr. Tong Ta-Chun's Outstanding Basic Medical Research Award on Oncology
2010 Outstanding Achievement Award, Wang Ming-Ning Memorial Foundation
2011 National Professorship, Ministry of Education
2013 Professorship, National Taiwan University
2009Recipient
Muh-Hwa Yang,M.D.,Ph.D.(楊慕華)
Institute of Clinical Medicine,National Yang Ming University School of Medicine,Taipei,Taiwan
Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital,Taiwan
2009Recipient
Muh-Hwa Yang,M.D.,Ph.D.(楊慕華)
Institute of Clinical Medicine,National Yang Ming University School of Medicine,Taipei,Taiwan
Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital,Taiwan
❖ Research Intersts:
Cancer Biology, Medical Oncology, Hematology, Internal medicine
❖ Education:
Aug 2010~Jul 2011 Visiting Scientist, M.D. Anderson Cancer Center, Houston, TX, USA
Aug 2006~Jul 2007 Post-Doctoral Fellow, Institute of Biochemisty and Molecular Biology, National Yang Ming University, Taipei, Taiwan
Sep 2003~Jul 2006 Ph.D, Institure of Clinical Medicine, National Yang Ming University, Taipei, Taiwan
Sep 1987~Jul 1994 M.D., Faculty of Medicine, National Yang Ming University, Taipei, Taiwan
❖ Academic Positions:
Mar 2015~present Director, Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taiwan
Aug 2013~present Professor, Institute of Clinical Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan
Aug 2013~present Adjunct Professor, Institute of Biotechnology in Medicine, Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan
Aug 2014~present Adjunct Research Fellow, Genomic Research Center, Academia Sinica, Taipei, Taiwan
Aug 2014~present Director, Genomic Research Center, National Yang-Ming University, Taipei, Taiwan
Aug 2013~present Director, Immunology Research Center, National Yang-Ming University, Taipei, Taiwan
Sep 2002~present Attending Physician, Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taiwan
Dec 2012~Jul 2014 Adjunct Associate Research Fellow, Genomic Research Center, Academia Sinica, Taipei, Taiwan
Aug 2007~Jul 2013 Assistant Professor, Institute of Clinical Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan
Aug 2002~Jan 2007 Instructor, Faculty of Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan
❖ Honors and Awards:
2005: Scholar-in-Training Award, 97th American Association for Cancer Research
2005: Award of Best Research Project, Taiwan Society of Hematology
2006: Award of Distinguished Thesis, Taiwan Society of Hematology
2007: Award of the Best Research Project, 12th Taiwan Joint Cancer Conference
2008: Award of Distinguished Thesis, Tien-Te Lee Biomedical Foundation, Taiwan
2008: Ta-Yu Wu Memorial Award, National Science Council, Taiwan
2009: Award of Distinguished Thesis, Taiwan Society of Hematology
2009: Award of the Best Research Project, 14th Taiwan Joint Cancer Conference
2009: Dr. Ta-Cheng Tung Memorial Award for Basic Cancer Research, Chinese Oncology Society, Taiwan
2009: First prize of Distinguished Thesis, Taipei Veterans General Hospital
2010: Award of the Best Research Project, 15th Taiwan Joint Cancer Conference
2011: First prize of Distinguished Thesis, Taipei Veterans General Hospital
2011: Young Scientist Research Award, Tien-Te Lee Biomedical Foundation, Taiwan
2011: Award for Junior Research Investigator, Academia Sinica
2011:Distinguished research award, National Yang-Ming University
2012: Outstanding Research Award, National Science Council, Taiwan
2013: First prize of Distinguished Thesis, Taipei Veterans General Hospital
2013:Distinguished research award, National Yang-Ming University
2014: Third prize of Distinguished Thesis, Taipei Veterans General Hospital
2014:Excellent teaching award, National Yang-Ming University
2015:Chien-Tien Hsu Outstanding Cancer Research Award, The Chinese Oncology Society
2015:Bio-medical Technology, 13th Y. Z. Hsu Scientific Paper Award